Parenteral applizierte Antipsychotika bei Agitation und Aggression

G. Utzerath; D. Reske; E. Gouzoulis-Mayfrank

doi:10.1055/s-0041-109986

Fortschritte der Neurologie · Psychiatrie, Table of Contents

Fortschr Neurol Psychiatr 2015; 83(12): 665-675
DOI: 10.1055/s-0041-109986

Übersicht

Parenteral applizierte Antipsychotika bei Agitation und Aggression

Parenteral Antipsychotics in the Treatment of Agitation and Aggression

G. Utzerath

,

D. Reske

,

E. Gouzoulis-Mayfrank

Abstract

Zusammenfassung

In dieser Übersichtsarbeit wird die wissenschaftliche Datenlage zu den Wirkstoffen Benperidol intravenös, Aripiprazol intramuskulär, Ziprasidon intramuskulär, Haloperidol intramuskulär sowie Loxapin inhalativ bezüglich ihrer Wirksamkeit und Verträglichkeit sowie pharmakodynamischen und pharmakokinetischen Eigenschaften präsentiert. Zudem wird der Einsatz bei Zuständen von Anspannung, Erregung und Aggression im Hinblick auf mögliche Vor- und Nachteile vergleichend diskutiert.

Abstract

This overview presents the current scientific data on intramuscular administration of benperidole, aripiprazole, ziprasidone, and haloperidole and on inhaled loxapine with regard to their efficacy and tolerability as well as their pharmacodynamic and pharmacokinetic properties. In addition, the possible advantages and disadvantages of the different substances are compared when administered to patients who show tension, agitation and aggression.

Schlüsselwörter

Agitation - Aggression - parenterale atypische Antipsychotika - parenterale typische Antipsychotika - intramuskulär - intravenös

Key words

agitation - aggression - parenteral atypical antipsychotics - parenteral typical antipsychotics - intramuscular - intravenous

Full Text

References

Literatur
1 TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 2003; 327: 708-713
2 McAllister-Williams RH, Ferrier IN. Rapid tranquillisation: time for areappraisal of options for parenteral therapy. Br J Psychiatry 2002; 180: 485-489
3 Huf G, da Silva Freire Coutinho E et al. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro-Brazil: a prevalence study. BMC Psychiatry 2002; 2: 4
4 Fachinformation Aripiprazol intramuskulär (7,5 mg/ml Injektionslösung). Stand 04.2015
5 Leggio GM, Salomone S, Bucolo C et al. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol 2013; 719: 25-33
6 Lee BJ, Lee SJ, Kim MK et al. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clin Psychopharmacol Neurosci 2013; 11: 60-66
7 Food and Drug Administration. Im Internet: www.fda.gov ; Stand 2015
8 Davies MA, Sheffler DJ, Roth BL. Aripiprazol: A novel atypical anti-psychotic drug with a uniquely robust pharmacology. CNS Drug Rev 2004; 10: 317-336
9 Naber D, Lambert M. Aripiprazole: a new atypikal antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1213-1219
10 Boulton DW, Kollia G, Mallikaarjun S et al. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clin Pharmacokinet 2008; 47: 475-485
11 Volavka J, Czobor P, Citome L et al. J Clin Psychiatry. 2005; 66: 1362-1366
12 Zimbroff DL, Marcus RN, Manos G et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007; 27: 171-176
13 Tran-Johnson TK, Sack DA, Marcus RN et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68: 111-119
14 Andrezina R, Josiassen RC, Marcus RN et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology 2006; 188: 281-292
15 AWMF. Leitlinie Schizophrenie. 2007
16 Daniel DG, Currier GW, Zimbroff DL et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. J Psychiatr Pract 2007; 13: 170-177
17 Fachinformation Benperidol. Stand 04/2013
18 Seiler W, Wetzel H, Hillert A et al. Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application. Psychopharmacology 1994; 116: 457-463
19 Garbow L. Comparative studies of Halothane anesthesia and neuroleptic analgesia in thoracic surgery. Anaesthesist 1964; 13: 220-225
20 Collard J. Benperidol and placebo: a double blind study in neuroses during ambulatory treatment. Acta Neurol Belg 1964; 64: 353-355
21 Fachinformation Haloperidol. Stand 09.2013
22 Meyer-Massetti C, Cheng CM, Sharpe BA et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?. J Hosp Med 2010; 5: E8-E16
23 Granger B, Albu S. The haloperidol story. Ann Clin Psychiatry 2005; 17: 137-140
24 Dervaux A, Laqueille X. Tobacco and schizophrenia: therapeutic aspects. Encephale 2007; 33: 629-632
25 Calver L, Drinkwater V, Gupta R et al. Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomised controlled trial. BMC Psychiatry 2014; 13: 225
26 Suzuki H, Gen K, Takahashi Y. A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. Hum Psychopharmacol 2014; 29: 83-88
27 Bosanac P, Hollander Y, Castle D. The comparative efficacy of intramuscular antipsychotics for the management of acute agitation. Australas Psychiatry 2013; 21: 554-562
28 Powney MJ, Adams CE, Jones H. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 2012; 11
29 Satterthwaite TD, Wolf DH, Rosenheck RA et al. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry 2008; 69: 1869-1879
30 EMA assessment report. 2012 Im Internet: http://www.ema.europa.eu ; Stand: 04.2015
31 Glazer WM. Does loxapine have “atypical” properties? Clinical evidence. J Clin Psychiatry 1999; 60: 42-46
32 Fachinformation Loxapin. Stand: 10.2014
33 Heel RC et al. Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. Drugs 1978; 15: 198-217
34 Tuason VB. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. J Clin Psychiatry 1986; 47: 126-129
35 Chakrabarti A et al. Loxapine for schizophrena. Cochrane Database Syst Rev 2007; 4: CD001943
36 Lesem MD, Tran-Johnson TK, Riesenberg RA et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 2011; 198: 51-58
37 Allen MH, Feifel D, Lesem MD et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72: 1313-1321
38 Kwentus J, Riesenberg RA, Marandi M et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord 2012; 14: 31-40
39 Dolovich MB, Macintyre NR, Anderson PJ et al. Consensus statement: aerosols and delivery devices. J Aerosol Med 2000; 13: 291-300
40 Casas M. Smoking in affective psychosis: review about nicotine use in bipolar and schizoaffective disorders. Adicciones 2011; 23: 65-75
41 Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992; 149: 1189-1194
42 Fachinformation Ziprasidon. Stand: 01.2014
43 Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Ther 2009; 26: 739-748
44 Jangro WC, Preval H, Southard R et al. Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study. Child Adolesc Psychiatry Ment Health 2009; 3: 9-14
45 Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry 2000; 61: 933-841
46 Brook S, Walden J, Benattia I et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl) 2005; 178: 514-523
47 Miceli JJ, Tensfeldt TG, Shiovitz T et al. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. Clin Ther 2010; 32: 472-491
48 Mautone A, Scarone S. Transition from ziprasidone IM to oral formulation in agitated paents with acute exacerbation of schizophrenia: an open trial. Pharmacopsychiatry 2011; 44: 173-178
49 Daniel DG, Potkin SG, Reeves KR et al. Intramuscular (IM) ziprasidone 20mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology 2001; 155: 128-134
50 Leucht S. Benperidol for schizophrenia. Cochrane Database Syst Rev 2005; 2
51 Komossa K, Rummel-Kluge C, Hunger H et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;
52 Benkert O. Wechsel des Antipsychotikums. In: Benkert O, Hippert H, Hrsg Kompendium der Psychiatrischen Pharmakotherapie. Heidelberg: Springer Medizin; 2014: 347-349
53 Khanna P, Suo T, Komossa K et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2014; 1
54 Rote Liste. Im Internet: www.online.rote-liste.de ; Stand: 06.2015